Financials · MCRB

Seres Therapeutics Inc. (MCRB) financials

For the twelve months ended Sep 30, 2026, Seres Therapeutics Inc. reported $2.13M of revenue and -$46.95M of net income.

Revenue, TTM
$2.13M
Revenue growth, YoY
+505.4%
Net income, TTM
-$46.95M
Net margin
-2209.6%
Free cash flow, TTM
-$63.97M
EPS, diluted, TTM
-$5.02
Cash
$17.53M
P/S
6.72
Market cap
$14.3M
Annual revenue$789.0K
FY2016FY2025
Annual net income$5.70M
FY2016FY2025
Annual free cash flow$865.0K
FY2016FY2025

MCRB revenue and earnings growth

MCRB revenueQ3 2026$593.0K

Quarter YoY
+68.9%
QoQ
-19.4%
5Y CAGR
-52.7%

MCRB revenue was $593.0K in fiscal Q3 2026 (ended Sep 30, 2026), up 68.9% from a year earlier and down 19.4% from the prior quarter. For the full fiscal 2025 it was $789.0K, compared with $0 in fiscal 2024. Compound annual growth was -52.7% over 5 years.

MCRB net incomeQ3 2026-$16.29M

FY YoY
42x

MCRB net income was -$16.29M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $8.20M a year earlier. For the full fiscal 2025 it was $5.70M, up about 42-fold from fiscal 2024. Fiscal 2025 is the highest of the 13 fiscal years on file.

MCRB EPSQ3 2026-$1.63

MCRB diluted EPS was -$1.63 in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0.94 a year earlier. For the full fiscal 2025 it was $0.64, compared with $0.00 in fiscal 2024.

MCRB free cash flowQ3 2026-$10.48M

MCRB free cash flow was -$10.48M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $2.20M a year earlier. For the full fiscal 2025 it was $865.0K, compared with -$148.99M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue$789.0K$0$0$7.13M$144.93M$33.22M$34.51M$28.27M$32.10M$21.77M
Research and development$49.06M$64.60M$117.60M$109.65M$141.89M$90.57M$80.14M$95.95M$89.45M$81.99M
Selling, general and admin$39.16M$53.18M$77.50M$70.26M$69.26M$30.77M$24.75M$32.60M$34.04M$32.62M
Operating income-$93.97M-$121.31M-$195.10M-$179.91M-$64.49M-$88.13M-$71.88M-$100.28M-$91.39M-$92.84M
Income tax$0$0$0$0$0$0$0$0$0$0
Net income$5.70M$136.0K-$113.72M-$250.16M-$65.58M-$89.13M-$70.28M-$98.94M-$89.38M-$91.58M
EPS, basic$0.64$0.00-$17.77-$46.20-$14.40-$22.40-$24.80-$48.60-$44.20-$46.00
EPS, diluted$0.64$0.00-$17.77-$46.20-$14.40-$22.40-$24.80-$48.60-$44.20-$46.00
Diluted shares8.9M7.8M6.4M5.4M4.6M4.0M2.8M2.0M2.0M2.0M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$45.77M$39.46M$136.15M$171.22M$188.00M$116.05M$65.13M$85.93M$36.20M$55.94M
Short-term investments--$0$18.31M$110.70M$137.57M$29.69M-$113.89M$138.70M
Receivables$157.0K$0---$9.39M$1.78M---
Inventory--$29.65M$0------
Current assets$49.38M$38.67M$175.41M$194.76M$303.63M$268.78M$100.19M$92.67M$155.08M$198.37M
Total assets$138.19M$139.81M$358.60M$348.78M$354.86M$342.94M$132.44M$120.47M$189.52M$272.65M
Current liabilities$19.32M$41.22M$98.66M$85.60M$82.26M$46.41M$45.99M$42.04M$31.63M$30.46M
Total debt--$110.00M$50.00M$24.05M$25.00M$25.00M---
Total liabilities$93.97M$126.03M$403.46M$338.00M$223.35M$168.19M$180.76M$168.52M$128.82M$140.01M
Shareholders' equity$44.22M$13.78M-$44.86M$10.78M$131.51M$174.75M-$48.32M-$48.05M$60.70M$132.63M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow$1.12M-$148.61M-$117.35M-$228.82M$6.69M-$93.61M-$76.52M-$62.85M-$75.52M$43.92M
Capital expenditures$252.0K$380.0K$7.97M$9.82M$9.57M$591.0K$1.00M$1.94M$4.68M$21.49M
Free cash flow$865.0K-$148.99M-$125.33M-$238.64M-$2.88M-$94.20M-$77.52M-$64.79M-$80.20M$22.43M
Investing cash flow-$42.0K$142.29M$10.58M$82.43M$64.09M-$158.89M-$30.52M$112.32M$55.70M-$65.59M
Financing cash flow$13.90M-$90.37M$71.70M$129.60M$1.18M$303.42M$86.23M$268.0K$83.0K$2.14M
Share repurchases--------$33.0K-
Stock-based compensation$10.84M$20.97M$34.10M$25.48M$20.22M$8.82M$8.34M$16.64M$17.36M$16.86M
Depreciation and amortization$4.13M$5.47M$6.24M$6.63M$5.95M$6.58M$7.60M$7.86M$7.26M$4.21M

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY---100.0%-95.1%336.3%-3.7%22.1%-11.9%47.5%-
Net income growth, YoY4088.2%---------
Operating margin-11910.1%---2524.0%-44.5%-265.3%-208.3%-354.8%-284.7%-426.5%
Net margin721.9%---3509.5%-45.2%-268.3%-203.7%-350.0%-278.4%-420.7%
Free cash flow margin109.6%---3347.9%-2.0%-283.6%-224.7%-229.2%-249.8%103.0%
Return on equity12.9%1.0%--2319.9%-49.9%-51.0%---147.3%-69.0%
Return on assets4.1%0.1%-31.7%-71.7%-18.5%-26.0%-53.1%-82.1%-47.2%-33.6%
Current ratio2.560.941.782.283.695.792.182.204.906.51
Debt to equity---4.640.180.14----

Source: XBRL data Seres Therapeutics Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported May 7, 2025.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

MCRB peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
MCRB$2.13M+505.4%-$46.95M-2209.6%$14.3M
LLY$86.46B+45.5%$27.58B31.9%$1.36T
JNJ$99.33B+7.8%$16.09B16.2%$687.89B
ABBV$66.01B+10.7%$10.34B15.7%$521.50B
MRK$67.38B+4.9%$2.45B3.6%$364.26B
NVS$54.53B+8.4%$13.98B25.6%$306.26B
AZN$58.74B+8.6%$10.22B17.4%$286.03B
ABT$48.23B+10.0%$4.70B9.7%$187.95B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$184.33B

MCRB FAQ

7 questions
  • What is MCRB revenue?
    Seres Therapeutics Inc. (MCRB) reported $2.13M of revenue for the twelve months ended Sep 30, 2026. That is up 505.4% from the year before. Revenue for fiscal 2025 was $789.0K.
  • Is MCRB profitable?
    No. Seres Therapeutics Inc. reported a net loss of $46.95M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does MCRB have?
    Seres Therapeutics Inc. reported $17.53M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • What is MCRB free cash flow?
    Seres Therapeutics Inc. generated -$63.97M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$63.94M less capital expenditures.
  • What is MCRB earnings per share?
    Diluted earnings per share were -$5.02 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did MCRB last report financial results?
    The latest statements here come from Seres Therapeutics Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
  • Where does this MCRB financial data come from?
    Quantisnow builds these statements from the structured XBRL data Seres Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.